Form 4: Kyntra Bio Director Receives Stock Option Grant

Director Maykin Ho was granted 7,000 stock options in Kyntra Bio, Inc. as part of a standard equity compensation package.

Summary

• Director Maykin Ho acquired 7,000 stock options in Kyntra Bio, Inc. (KYNB) on June 12, 2026.
• The options have an exercise price of $7.13 per share.
• The options are set to expire on June 11, 2036.
• The grant vests in four equal quarterly installments.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in minor potential future dilution for existing shareholders.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $7.13 exercise price.

Future Outlook

The options vest in four equal quarterly installments, indicating a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members remain incentivized to oversee long-term growth.

Comparison to Industry Standards

• The use of quarterly vesting schedules is consistent with standard industry practices for board compensation.
• The grant size is typical for non-executive director compensation in small-cap biotech firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of the 7,000 options in four equal quarterly installments.

Key Dates

Keywords

Kyntra Bio, KYNB, Form 4, Insider Trading, Stock Options, Director Compensation